Placental Derived Stem Cells

Funding Type: 
New Cell Lines
Grant Number: 
RL1-00658
Investigator: 
ICOC Funds Committed: 
$0
Public Abstract: 
Diseases that can potentially be cured by the use of stem cell treatment afflict significant number of individuals. Currently, the application of this treatment is limited because of the limited supply of appropriate amounts of stem cells, and because it is necessary to match certain characteristics of the donor’s and host’s immune systems. In addition to the need of massive supply of cells to cure patients, stem cells from diverse genetic backgrounds are required to study the apparent variation in responses to drugs, and to develop individualized medicine. Therefore, more new and well-defined stem cell lines are needed. We have carried out pioneering studies demonstrating that human placenta may be used as a source of these stem cell lines. These cell lines derived from human placenta have the potential to contribute to research in stem cell biology and clinical applications. Furthermore, placentas are readily available from all racial and ethnic groups. As this approach does not require the donation or use of either human embryos or eggs, it will eliminate ethical concerns. Further, it will help to overcome the limitations inherent in obtaining excess human embryos from different populations in our society. We are confident that these stem cell lines will be used in regenerative medicine research and cell replacement therapies, as well as in the development of new treatment approaches. Ultimately, the knowledge and experience produced by the work proposed will contribute to the goal of making stem cell transplantation and new medical approaches available to a much broader group of patients and contribute significantly to CIRM’s goal of providing new cures for human disease.
Statement of Benefit to California: 
Diseases that can potentially be cured by the use of stem cell treatment afflict significant number of individuals in California. The application of this treatment is limited because of the limited supply of appropriate stem cell lines, as it is necessary to match certain characteristics of the donor’s and host’s immune systems. In addition, stem cells from diverse genetic backgrounds are needed to evaluate the apparent variation in responses to drugs and to develop individualized medicine. We have carried out pioneering studies demonstrating that human placenta may be used as a source of such stem cell lines. These cell lines derived from human placenta will contribute to research in stem cell biology and clinical applications. Furthermore, placentas are readily available from all racial and ethnic groups. As this approach does not require the donation or use of either human embryos or eggs, it will greatly reduce the ethical concerns, and may help overcome the limitations inherent in obtaining excess human embryos. As such, we will be able to generate stem cell lines that will reflect the diverse population of California. These stem cell lines will be used in regenerative medicine research and cell replacement therapies as well as the development of new treatment approaches. The enhanced and extended lives of the individuals will represent an evident benefit; the savings to the health care system as a consequence of their cure will straightforwardly benefit all California taxpayers. The use of these stem cell lines from diverse genetic backgrounds, will enable scientists to study the apparent variation in responses to drugs and treatment, and to develop individualized medicine for the diverse population in California. Ultimately the knowledge and experience produced by the work proposed will contribute to the goal of making stem cell transplantation and new medical approaches available to a much broader group of patients, thus greatly extending the benefits to the affected individuals and to the taxpayers of California.

© 2013 California Institute for Regenerative Medicine